Pink News is reporting an experimental HIV vaccine developed by Johnson & Johnson has failed at clinical trial stage in a devastating setback to HIV and AIDS research. A mid-stage study called Imbokodo found that the vaccine’s efficacy at preventing HIV transmission was just 25.2 per cent, the National Institutes of Health said in a press release. The Phase 2b proof-of-concept study enrolled 2,637 women between the ages of 18 and 35 across five African countries, where young women account for 60 per cent of new HIV cases. While the vaccine was found to be safe with no serious adverse affects, it also produced a low immune response in study participants. Women who took part in the clinical trial were randomly assigned either a placebo or the real version of the vaccine when the study began in November 2017. Researchers found that 63 women who received the placebo and 51 who received the vaccine went on to contract HIV.